Immune Netw.  2005 Mar;5(1):11-15. 10.4110/in.2005.5.1.11.

Human Activated Lymphocyte Treated with Anti-CD3, CD16, CD56 Monoclonal Antibody and IL-2

• Hong SM
• Lee DW
• Kang JG
• Kim HS
• Cho SH

• KMID: 2150584
• DOI: http://doi.org/10.4110/in.2005.5.1.11

Abstract

BACKGROUND
Throughtout the last three decades, the therapy of leukemias and lymphoma has set the stage for curative cancer therapy in systemic malignant disease. This was the result of an integrated work of basic reaserch and clinical investigators leading to more aggressive albeit tolerable protocol of chemotherapy and radiotherapy. High dose therapy marks the most elaborated strategies in this field today. However, intensification of conventional therapeutic modalities as mentioned has to be based on new approaches and the exploration of new antineoplastic mechanisms. This insight has resulted in immune therapy of cancer. Among the cells of the immune system, natural killer (NK) cells and T cells are of major interest for the development of therapeutic strategies. METHODS: Cytotoxicity to target cells was measured by LDH release method, Characterization of activated lymphocyte was measured by Flow cytometry analysis. Anti-CD3, 16, 56 monoclonal antibody and IL-2 were used for the activation of NK and T cell. The analysis of effect of activated lymphocyte, in vivo, were used by Balb/c nude mouse. RESULTS AND CONCLUSION: Cytotoxicity to K562 cells was significantly higher in the mixture group of NK and T cells than that of a group of activating T cells. The survivors and the rate of reduction of size of tumor craft of nude mouse group treatment with activated lymphocyte was higher than that of the group without treatment with activated lymphocyte. Therefore, this results are suggested that the activated lymphocytes by anti-CD3, CD16 and CD56 can reduce the malignancy effect of lymphoma.

Keyword

Activated lymphocyte; CD3; CD16; CD56; IL-2; natural killer cell; T cell; human; nude mouse; lymphoma; K562; raji

MeSH Terms

Animals
Drug Therapy
Flow Cytometry
Humans*
Immune System
Interleukin-2*
K562 Cells
Killer Cells, Natural
Leukemia
Lymphocytes*
Lymphoma
Mice
Mice, Nude
Radiotherapy
Research Personnel
Survivors
T-Lymphocytes
Interleukin-2